A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

Recruiting now · Phase 2

Conditions studied: Resectable Lung Non-Small Cell Carcinoma

In brief

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Key facts

Study ID

NCT06775275

Run by

The First Affiliated Hospital of Guangzhou Medical University

People needed

60

Starts

2024-09-24

Expected to finish

2029-12-31

Last updated by the study team

2025-01-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Resectable NSQ NSCLC
• Age 18-65 years
• male or female
• ECOG 0-1
• Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
• Subjects must have adequate pulmonary function for the intended pneumonectomy;

You may not qualify if…

• SCLC or SQ NSCLC
• previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
• patients who have previously used anti-angiogenic drugs;
• allergic to any component of the study drug or chemotherapy drugs
• patients with any severe and or uncontrolled disease

Where it is running

• Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.